DocWire News recently spoke with Chris Ambrose, MD, MBA, Franchise Head, US BioPharmaceuticals Medical, Respiratory at AstraZeneca, and Jean Pierre Llanos Ackert, Executive Medical Director, Global Medical Affairs Lead – Tezepelumab & Pulmonary Pipeline. We discussed the NAVIGATOR study, which demonstrated robust efficacy in a population of patients living with severe uncontrolled asthma.
Questions Dr. Ambrose discusses:
- Can you provide us with an overview of the NAVIGATOR study?
- Were the results from the NAVIGATOR study surprising?
- Did the study have any limitations?
- What are the clinical implications of the NAVIGATOR study findings?
